Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05687188 · ClinicalTrials.gov registry record
Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations
A clinical trial of Pancreatic Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- 125
- Enrollment target
- 2
- Study locations
NCT05687188: Recruiting study of Pancreatic Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT05687188 is a study of Pancreatic Cancer that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 125 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (68% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05687188, a study of Pancreatic Cancer, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- 125 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will evaluate obesity-mediated mechanisms of pancreatic carcinogenesis in minority populations.
Primary Outcome
Investigators will compare gene prevalence, type and expression of genetic mutations and radiomic features in African American participants vs Non-Hispanic White participants
Conditions Studied
Interventions
- OTHER Data Collection
- OTHER Blood Sample Collection
- OTHER Tissue Sample Collection
- OTHER Medical Image Collection
Study Locations (2)
Florida
- Moffitt Cancer Center - Tampa
Mississippi
- University of Mississippi Medical Center - Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2023-02-22 |
| Est. Completion | 2026-12 |
What NCT05687188 shows while recruiting
NCT05687188 is an observational study that tracks outcomes without assigning an intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 4 interventions - of which Data Collection is the first listed.
NCT05687188 reports a single indexed study location in Florida, Mississippi.
Frequently Asked Questions
What is clinical trial NCT05687188 about?
NCT05687188 is a clinical study titled "Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations". This study will evaluate obesity-mediated mechanisms of pancreatic carcinogenesis in minority populations.
What is the current status of trial NCT05687188?
This trial is currently recruiting. The enrollment target is 125 participants. The study started on 2023-02-22. Estimated completion is 2026-12.
What conditions does trial NCT05687188 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT05687188?
The interventions under investigation include: Data Collection (OTHER), Blood Sample Collection (OTHER), Tissue Sample Collection (OTHER), Medical Image Collection (OTHER).
Who is sponsoring clinical trial NCT05687188?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05687188 being conducted?
This trial has 2 study locations across Florida, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05687188's enrollment target sits among peer trials
125 90th of 278 higher than 187 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI